Utama › Leukemia › Massachusetts › Boston
Kajian klinikal Leukemia di Boston, MA
25 kajian untuk Leukemia sedang mencari peserta di lokasi dalam dan sekitar Boston (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Mengambil pesertaFasa 2
- Dana-Farber Cancer Institute, Boston
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Mengambil peserta
- Dana-Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Mengambil pesertaFasa 3
- Research Site, Boston
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Mengambil pesertaFasa 2
- Massachusetts General Hospital, Boston
CIML NK Cells With Venetoclax for AML
Mengambil pesertaFasa 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Mengambil pesertaFasa 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Mengambil pesertaFasa 1
- Beth Israel Deaconess Medical Center, Boston
ALL Backbone in AYAs
Mengambil pesertaFasa 2
- Dana Farber Cancer Institute, Boston
Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
Mengambil peserta
- Mass General Brigham Cancer Institute, Boston
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Mengambil pesertaSukarelawan sihat dialu-alukan
- Dana-Farber Cancer Institute, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Mengambil pesertaFasa 1
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Mengambil pesertaFasa 1
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Mengambil pesertaFasa 1/2
- Dren Investigational Site, Boston
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Mengambil pesertaFasa 1
- Dana-Farber Cancer Institute, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Mengambil pesertaKajian pemerhatian
- Dana-Farber Cancer Institute, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Mengambil pesertaFasa 2/3
- Dana-Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Mengambil peserta
- Massachusetts General Hospital Cancer Center, Boston
Shwachman Diamond Syndrome Registry and Study
Mengambil pesertaKajian pemerhatian
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Revumenib in Combination With 7+3 + Midostaurin in AML
Mengambil pesertaFasa 1
- Dana-Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Mengambil pesertaFasa 1
- Massachusetts General Hospital, Boston
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Mengambil pesertaFasa 1/2
- Dana-Farber Cancer Institute, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Mengambil pesertaFasa 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
Mengambil pesertaFasa 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
Mengambil peserta
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
HEME Home Transfusion Program
Mengambil peserta
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Kajian Leukemia di bandar lain
- Houston, TX28 kajian
- New York City, NY19 kajian
- Los Angeles, CA16 kajian
- Chicago, IL16 kajian
- Durham, NC13 kajian
- Baldwin Park, CA12 kajian
- Columbus, OH12 kajian
- Nashville, TN12 kajian
- Philadelphia, PA12 kajian
- Milwaukee, WI11 kajian
- Atlanta, GA11 kajian
- Seattle, WA11 kajian
Kajian lain di Boston
- Kanser Payudara111 kajian
- Kanser Paru-paru Bukan Sel Kecil90 kajian
- Kanser (semua jenis)86 kajian
- Kanser Kolorektal63 kajian
- Kanser Metastatik63 kajian
- Kanser Paru-paru62 kajian
- Kanser Ovari61 kajian
- Kanser Prostat59 kajian
- Depresi52 kajian
- Kanser Endometrium50 kajian
- Kegagalan Jantung44 kajian
- Leukemia Mieloid Akut44 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.